image credit: Unsplash

BioCryst Announces FDA Approval of ORLADEYO, First Therapy to Prevent HAE Attacks in Adults

December 4, 2020

Via: BioSpace

BioCryst Pharmaceuticals, Inc. announced on Thursday that the U.S. Food and Drug Administration (FDA) has approved ORLADEYO (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and young patients 12 years and older. The approval was based on data from the Phase 3 APeX-2 trial, which showed that ORLADEYO could significantly reduce attacks at the 24-week mark. The reduction was sustained through 48 weeks in the study.

Read More on BioSpace